Resveratrol Affects Insulin Signaling in Type 2 Diabetic Goto-Kakizaki Rats

Resveratrol is a biologically active diphenolic compound exerting multiple beneficial effects in the organism, including anti-diabetic properties. This action is, however, not fully elucidated. In the present study, we examined effects of resveratrol on some parameters related to insulin signaling, and also on diabetes-associated dysregulation in Goto-Kakizaki (GK) rats with congenital type 2 diabetes. Resveratrol was given at the dose of 20 mg/kg b.w. for 10 weeks. It was shown that the expression and phosphorylation levels of insulin receptor in the skeletal muscle of GK rats were significantly decreased, compared with control animals. However, these changes were totally prevented by resveratrol. Liver expression of the insulin receptor was also reduced, but in this case, resveratrol was ineffective. Resveratrol was also demonstrated to significantly influence parameters of insulin binding (dissociation constant and binding capacity) in the skeletal muscle and liver. Moreover, it was shown that the expression levels of proteins related to intracellular glucose transport (GLUT4 and TUG) in adipose tissue of GK rats were significantly decreased. However, treatment with resveratrol completely abolished these changes. Resveratrol was found to induce normalization of TUG expression in the skeletal muscle. Blood levels of insulin and GIP were elevated, whereas proinsulin and GLP-1 diminished in GK rats. However, concentrations of these hormones were not affected by resveratrol. These results indicate that resveratrol partially ameliorates diabetes-associated dysregulation in GK rats. The most relevant finding covers the normalization of the insulin receptor expression in the skeletal muscle and also GLUT4 and TUG in adipose tissue.     

Bioactive peptides with antidiabetic properties: a review

Diabetes mellitus is a complex disorder characterised by insufficient insulin production or insulin resistance. Disease incidence is accumulating at a rapidly increasing rate, resulting in a considerable social, health and economic burden in the modern world. Bioactive peptides show significant potential for use in health management strategies, particularly as components of drugs and functional foods for diabetes treatment. Many antidiabetic bioactive peptides have been isolated and validated. The aim of this review was to update the state of knowledge of the origin, structural characteristics and action. Additionally, the potential mechanisms of bioactive peptides on key enzymes and proteins, such as α-amylase, α-glucosidase, glucagon-like peptides and dipeptidyl peptidase-IV, that participate in glycaemic level control from the intake of carbohydrates to blood glucose regulation were overviewed. This knowledge should facilitate research and industrial efforts to better understand and evaluate the potential of bioactive peptides with antidiabetic properties for blood glucose level management.     

Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs

Diabetes mellitus is a major healthcare problem. It is not only characterized by hyperglycemia and chronic complications, but in longer lasting diabetes and a longer living population, it is also associated with accelerated arterial ageing, which importantly contributes to cardiovascular complications. The accelerated arterial ageing in patients with diabetes should be considered separately from arterial ageing in patients without diabetes. Basic and clinical research have allowed better insight into the mechanisms of arterial ageing. In a simplified mechanistic way, it could be considered that the three tightly connected cornerstone characteristics of arterial ageing in patients with diabetes are: phenotypic presentation as endothelial dysfunction and arterial stiffness, and the underlying basic ageing-facilitating mechanism represented as the impaired expression of genetic longevity pathways. Currently, specific drugs for preventing/treating arterial ageing are not available. Therefore, we aimed to review the capacity of available drugs, particularly antidiabetic drugs, to interfere with the arterial ageing process. In the near future, these characteristics could help to guide therapy in patients with diabetes. Overall, it appears that arterial ageing could become a new target in diabetes. The expanding knowledge regarding the capability of antidiabetic drugs and other available drugs to inhibit/delay arterial aging is therefore essential.     

An augmented subcutaneous type 1 diabetic patient modelling and design of adaptive glucose control

In the present work, an augmented subcutaneous (SC) model of type 1 diabetic patients (T1DP) is proposed first by estimating the model parameters with the aid of nonlinear least square method using the physiological data. Next, a nonlinear adaptive controller is proposed to tackle two important issues of intra-patient variability (IPV) and uncertain meal disturbance (MD). The proposed patient model agrees quite well with the responses of one of the most popular existing nonlinear model used in the research of artificial pancreas. Further, the developed adaptive control is shown to be capable of providing desired glycemic control without feed-forward action for meal compensation or safety algorithms to avoid hypoglycemia. Due to the simple structure and capability of handling intra-patient variability of the adaptive controller, it can find immediate applicability in the development of the in-silico artificial pancreas.     

Relationship between Proinflammatory and Antioxidant Proteins with the Severity of Cardiovascular Disease in Type 2 Diabetes Mellitus

Type 2 diabetes mellitus patients are at significant risk of cardiovascular disease, however, the pathophysiology of these complications is complex and incompletely known in this population. The aim of this study was to compare the serum proteome of patients with type 2 diabetes mellitus presenting or not presenting cardiovascular disease with non-diabetic subjects to find essential proteins related to these cardiovascular complications. This cross-sectional study compares the serum proteome by a combination of protein depletion with 2D-DIGE (2-dimension Difference Gel Electrophoresis) methodology. The proteins differentially expressed were identified by MALDI TOF/TOF (Matrix-assisted laser desorption/ionization and Time-Of-Flight ion detector) or LC-MS/MS (Liquid Chromatography coupled to Mass-Mass Spectrometry). Type 2 diabetes mellitus patients with cardiovascular disease showed higher expression of plasma retinol binding protein and glutathione peroxidase-3 compared to those without cardiovascular disease and non-diabetic controls. These results show that proteins related to the inflammatory and redox state appear to play an important role in the pathogenesis of the cardiovascular disease in the type 2 diabetes mellitus patients.     

甜玉米芯多糖对胰岛素抵抗HepG2细胞糖代谢功能的影响

目的：探讨甜玉米芯多糖（sweet corncob polysaccharide，SCP）组分SCP-80-I对胰岛素抵抗HepG2（insulin resistant HepG2，IR-HepG2）细胞糖代谢功能的影响。方法：确立IR-HepG2细胞模型建立的最佳条件，并由此建立IR-HepG2细胞模型；分别以50、100、200、400 μg/mL剂量的SCP-80-I孵育细胞24 h，评价其对细胞葡萄糖消耗的影响，同时利用噻唑蓝法评价其细胞毒性；检测氧化应激标志物超氧化物歧化酶（superoxide dismutase，SOD）、丙二醛（malondialdehyde，MDA）及活性氧（reactive oxygen species，ROS）的水平，测定细胞内糖原积累水平及糖酵解关键限速酶己糖激酶（hexokinase，HK）、丙酮酸激酶（pyruvate kinase，PK）的活力。结果：确立以1×10－6 mol/L胰岛素处理24 h作为诱导IR-HepG2细胞形成的最佳条件，并成功建立IR-HepG2细胞模型；在孵育实验中，SCP-80-I能极显著增加IR-HepG2细胞的葡萄糖摄取量（P＜0.01），细胞活力随SCP-80-I质量浓度的增加呈先上升后下降的趋势；200 μg/mL SCP-80-I处理组与模型对照组相比，胞内MDA含量极显著下降，SOD活力极显著提高，ROS水平极显著下降（P＜0.01）；胞内糖原含量极显著增加（P＜0.01），HK与PK活力极显著增加（P＜0.01）。结论：推测SCP-80-I的降血糖功效与其缓解氧化应激所造成的肝脏细胞损伤，改善胰岛素抵抗肝脏细胞的糖代谢功能有关。